Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2. Brooklyn ImmunoTherapeutics LLC (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients…

News from Disruptive capital GP Limited